11 results about "Umbilical vein" patented technology

The invention discloses a combined evaluation method for in-vitro and in-vivo red fading and relieving effects of cosmetic raw materials, which comprises the following steps: in-vitro model evaluation: inducing a human immortalized umbilical vein endothelial cell model by adopting TNF-alpha, and detecting the secretion amount of a prostacyclin I2 factor to obtain a score of an in-vitro model; in-vivo model evaluation: adopting a chick embryo chorioallantoic membrane model, and obtaining a score of the in-vivo model according to the degree of vasoconstriction caused by the to-be-detected raw material sample acting on the chick embryo chorioallantoic membrane; and comprehensive evaluation: based on the score of the in-vitro model and the score of the in-vivo model, comprehensively evaluating the red fading and relieving efficacy of the raw material sample to be tested. According to the technical scheme, the defect that in the prior art, no cosmetic raw material soothing efficacy evaluation method for the vascular reactivity increasing mechanism exists is overcome, efficacy evaluation is more accurate, the method has the advantages of being comprehensive, short in test period, easy to operate, economical and convenient, and an effective reference basis is provided for screening and compounding schemes of red fading and soothing raw materials.

The anti-falling umbilical vein catheter comprises an umbilical vein catheter body with the inner end inserted into the body, a first buckle is embedded in the portion, located outside the body and close to the umbilical region, of the umbilical vein catheter body in a clamped mode, the first buckle is attached to the surface of the skin, and the first buckle and the skin are connected and fixed through a silk thread. A sterile gauze covering the umbilical vein catheter and the first buckle is laid on the abdomen of the child patient, a circle of wide bellyband is wound around the abdomen of the child patient and attached to the sterile gauze, a second buckle located on one side of the abdomen of the child patient is attached to the bottom of the wide bellyband in a pressing mode, and meanwhile the outer end of the umbilical vein catheter sequentially penetrates through the first buckle and the second buckle. When the wide-body bellyband is used, in order to prevent the umbilical vein catheter from falling off when the wide-body bellyband is loosened, the two connecting bands are arranged at the connecting end of the bellyband, in the dressing changing process, the half-winding section of the catheter can be temporarily transferred to the bottom of the connecting band which is not loosened, and the wide-body bellyband can further position and stabilize the sterile gauze.

The invention discloses a postpartum placenta blood vessel developing kit. The postpartum placenta blood vessel developing kit comprises polypropylene watercolor powder which is pre-packaged in a vacuum bottle and has the particle size of 100-300nm; the bagged normal saline is uniformly mixed with the polypropylene watercolor powder to form a polypropylene-based main developing agent; the blood vessel lock catch is used for clamping and closing the blood vessel and preventing the polypropylene-based main developing agent from flowing back through the umbilical cord blood vessel; the injector is used for respectively injecting the polypropylene-based main developing agent into the umbilical artery and the umbilical vein; the graduated scale is used for measuring the size of the placenta. By pre-preparing the dye, uniform concentration, sterility, reliability and simplicity and convenience in operation are ensured; the dye particle size can be controlled to avoid capillary blockage, and the developing quality is improved; the method can also meet diversified clinical requirements of multi-fetal, radiography verification, anticoagulation pretreatment and the like.

The invention belongs to the technical field of biological materials, and particularly relates to a rosa roxburghii tratt exosome microneedle patch for promoting skin wound healing and a preparation method of the rosa roxburghii tratt exosome microneedle patch. The roxburgh rose exosome microneedle patch for promoting skin wound healing comprises a patch base body and a microneedle array which are integrally formed, the microneedle array is distributed on the surface of the patch base body, and the patch base body and the microneedle array are made of degradable materials doped with roxburgh rose exosomes; after penetrating through a skin barrier, constructing a roxburgh rose exosome delivery channel and degrading, the roxburgh rose exosome can be uniformly released to a skin wound to accelerate migration of human immortalized keratinocytes, fibroblasts, human umbilical vein endothelium and other cells so as to promote repair and healing of skin tissues such as epidermis, dermis and subcutaneous tissues; according to the application, the application range of the roxburgh rose exosome is expanded, the roxburgh rose exosome is effectively utilized, and the technical problems that the efficacy of the roxburgh rose exosome is lack of research and the roxburgh rose exosome is difficult to effectively apply at present are solved.

The invention discloses an ultrasonic imaging method and an ultrasonic imaging system for a fetus in the middle-late pregnancy period. The method comprises the following steps: S220, obtaining three-dimensional ultrasonic data of the fetus in the middle-late pregnancy period; s230, according to the three-dimensional ultrasonic data, the long axis direction of the body area of the fetus in the middle-late pregnancy period is determined; s540, extracting information of a mid-late pregnancy target feature structure of the fetus from the three-dimensional ultrasonic data, wherein the mid-late pregnancy target feature structure comprises at least one of the following parts: gastric vesicle, spine bone, liver, umbilical vein, descending aorta, inferior vena cava, umbilical cord insertion position, umbilical cord, anterior abdominal wall, bladder, legs, umbilical artery and gallbladder; and S560, extracting at least one abdominal standard section of the fetus in the middle-late pregnancy period from the three-dimensional ultrasonic data according to the information of the long axis direction and the middle-late pregnancy target feature structure, and displaying the extracted abdominal standard section. According to the ultrasonic imaging method and the ultrasonic imaging system, the abdominal standard sections of the fetuses in the middle-late pregnancy period are automatically extracted according to the three-dimensional ultrasonic data collected at a time, a doctor does not need to manually extract the abdominal standard sections one by one, and the efficiency of extracting the abdominal standard sections and the quality of the extracted abdominal standard sections are improved.

The invention discloses a PINK1 inducible expression cell line of a porcine umbilical vein endothelial cell and a construction method and application thereof, a stable cell line with controllable PINK1 expression level is constructed by introducing a porcine PINK1 gene into the porcine umbilical vein endothelial cell and combining with an inducible expression system taking doxycycline as an inducer. The cell line is in a low-expression or non-expression state under the condition that an inducer is not added, and dose-dependent induced expression can be realized after doxycycline is added. Experimental results show that the induced expression of PINK1 can regulate and control the expression of angiogenesis related genes, activate mitochondrial autophagy related pathways under oxidative stress conditions, and influence the expression of cell proliferation and apoptosis related proteins at the same time. The cell line is clear in construction method and good in stability, can be used as an in-vitro model for researching angiogenesis, oxidative stress and related regulation and control mechanisms of porcine vascular endothelial cells, and has good practical value.

A method for neonatal monitoring includes catheterizing a neonatal patient via an implanted umbilical interface, infusing a signaling fluid into the neonatal patient via the neonatal PiCCO venous catheter, monitoring circulating blood for a hemodynamic signal via the neonatal PiCCO arterial catheter, and detecting the hemodynamic signal. Catheterizing the neonatal patient via the implanted umbilical interface includes inserting the neonatal PiCCO arterial catheter into an umbilical artery of the neonatal patient and inserting the neonatal PiCCO venous catheter into an umbilical vein of the neonatal patient.

The invention relates to the technical field of biological medicines, and particularly discloses application of a product for promoting WBP11 gene expression in preparation of a medicine for treating or preventing bronchial pulmonary dysplasia. The product for promoting WBP11 gene expression promotes proliferation of human primary umbilical vein endothelial cells by promoting WBP11 gene expression, and promotes the tube forming ability of the human primary umbilical vein endothelial cells in bronchial pulmonary dysplasia.

The present invention discloses a sheep umbilical cord and placenta development promoting feed, which comprises a TMR daily ration and rumen bypass coated folic acid, and the addition amount of the rumen bypass coated folic acid in each kilogram of feed dry matter is 16 mg. The invention relates to the field of animal nutriology and embryology, aims to improve the survival rate and growth performance of fetuses, and specifically comprises the following steps: adding rumen bypass coated folic acid of a specific dose into daily ration of pregnant sheep, and continuously feeding the pregnant sheep from mating to lambing. According to the method, the fetal umbilical cord diameter can be remarkably increased, the sheep umbilical vein cross section area can be improved, the nutrient substance transportation capability of the umbilical cord can be enhanced, the placenta structure and function can be improved, the placenta trophoblast cell density can be improved, and the maternal-fetal nutrient substance transmission efficiency can be enhanced. The method has the advantages of simplicity and convenience in operation, remarkable economic benefit and the like.

The application discloses a combined evaluation method for the in-vitro and in-vivo redness-reducing soothing effect of a cosmetic raw material, which comprises in-vitro model evaluation, adoption of a human immortalized umbilical vein endothelial cell model induced by TNF-alpha, acquisition of the in-vitro model score by detecting the secretion amount of prostacyclin I2 factor, in-vivo model evaluation, adoption of a chicken embryo chorioallantoic membrane model, acquisition of the in-vivo model score by the degree of blood vessel contraction caused by the action of the sample to be tested on the chicken embryo chorioallantoic membrane, and comprehensive evaluation of the redness-reducing soothing effect of the sample to be tested based on the in-vitro model score and the in-vivo model score. The technical scheme of the application makes up for the defect of the prior art that there is no cosmetic raw material soothing effect evaluation method for the mechanism of increased vascular reactivity, the effect evaluation is more accurate, and the method has the advantages of comprehensiveness, short test cycle, simple operation, economy and convenience, and provides an effective reference for the screening and compounding scheme of redness-reducing soothing raw materials.

The invention relates to the technical field of function testing of cosmetic raw materials, and particularly discloses a method and a model for evaluating in-vitro red fading and relieving effects of cosmetic raw materials, and the method comprises the following steps: inducing human immortalized umbilical vein vascular endothelial cells by adopting a TNF-alpha inducer to establish a red fading and relieving in-vitro model; the method specifically comprises the following steps: after inoculating and culturing human immortalized umbilical vein vascular endothelial cells, setting a control group, a modeling group, a positive drug group and a sample group, respectively adding special culture mediums into the control group and the modeling group, adding an epoxidase inhibitor into the positive drug group, adding a raw material sample to be detected into the sample group, and pre-treating; then adding a TNF-alpha inducer into each group except the control group, and carrying out induction culture; the prostacyclin I2 factor is adopted as a detection index to evaluate the red fading and relieving effects of the raw material sample to be detected. The method is short in test period, simple to operate, economical and convenient, and provides reliable data for further research of efficacy verification in the cosmetic industry.